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ICU = intensive care unit; MRSA = methicillin-resistant Staphylococcus aureus; PPM = potentially pathogenic microorganism; SDD = selective
decontamination of the digestive tract; VAP = ventilator-associated pneumonia; VRE = vancomycin-resistant entercocci.
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Recent meta-analyses have shown that the use of selective
decontamination of the digestive tract (SDD) can reduce the
occurrence of ventilator-associated pneumonia (VAP) [1–5].
Two of these analyses also demonstrated a significant
reduction in intensive care unit (ICU) mortality [4,5].
However, the effectiveness of SDD has remained
controversial [6,7]. Although SDD has received considerable
attention in European ICUs, North American intensivists have
been uniformly resistant to the incorporation of SDD as
standard care [8,9]. One of the main concerns is the fear of
emergence of selection for resistant organisms. Furthermore,
in the guidelines for the prevention of nosocomial pneumonia
published in 1997, the Centers for Disease Control and
Prevention stated that available data do not justify the routine
use of SDD in ICU patients [10].
We recently performed a single-center, prospective, controlled,
randomized trial on the use of SDD that showed improved
survival of ICU patients treated with SDD [11]. Importantly, the
study also demonstrated that colonization with resistant
bacteria decreased, which is opposite to the expectation of the
skepticists about SDD in intensive care patients.
The concept on which SDD is based
Nosocomial infections are caused by a limited number of
potentially pathogenic microorganisms (PPMs) such as
Streptococcus pneumoniae, Haemophilus influenzae,
Staphylococcus aureus, Moraxella catarrhalis, Escherichia
coli and Candida albicans that are carried by healthy people,
and by opportunistic aerobic Gram-negative bacilli such as
Klebsiella, Proteus, Morganella, Enterobacter, Citrobacter,
Serratia, Acinetobacter and Pseudomonas species that are
present in individuals with underlying pathology.
One method for preventing nosocomial infections by these
PPMs is the use of SDD [12]. This technique combines
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Abstract
Several emotional responses may be invoked in critical care physicians when confronted with selective
decontamination of the digestive tract (SDD). Although recent meta-analyses have shown that the use
of SDD reduces the occurrence of ventilator-associated pneumonia and improves ICU survival, the
effectiveness of SDD has remained controversial. We recently concluded a large randomized,
controlled trial on the use of SDD that showed improved survival of ICU patients treated with SDD. A
second concern regarding use of SDD has been the fear for the emergence of antimicrobial
resistance. Interestingly, a recently published study did not confirm this fear, and our recently finished
study even demonstrated a decline in colonization with P. aeruginosa and enterobacteriaceae that
were resistant against tobramycin, ceftazidime, imipenem and ciprofloxacin. The hopes are that this
study will at long last end the debate about the efficacy and safety of SDD in critically ill patients.
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enterally applied, nonabsorbable antibiotics and parenteral
antibiotics. The rationale for SDD lies in the appreciation that
the majority of ICU infections are caused by the
aforementioned pathogens, predominantly the Gram-negative
aerobic bacteria. These pathogens may be present prior to
admission to the ICU. They give rise to so-called primary
endogenous infections. Secondary endogenous infections
occur at later time points during the stay in the ICU, are
caused by hospital-acquired organisms, and are preceded by
colonization of the oropharynx, the stomach and the gut.
These infections are much less frequent [13].
The goal of SDD is to prevent, or to eradicate if initially
present, oropharyngeal and gastrointestinal carriage of
PPMs, especially hospital PPMs, leaving the indigenous flora,
which are thought to protect against overgrowth with
resistant bacteria, largely undisturbed [13].
SDD classically consists of four aspects. The first is selective
eradication of PPMs in the oral cavity by application of
orabase, containing nonabsorbable antibiotics (e.g. polymyxin
B, tobramycin and amphotericin B), and decontamination of
the rest of the digestive tract by local administration (through
a nasogastric tube) of the aforementioned antibiotics.
Another method is systemic prophylaxis (e.g. cefotaxime) to
prevent respiratory infections that may occur early during the
ICU stay, caused by commensal respiratory flora (S.
pneumoniae and H. influenzae). The third aspect is optimal
hygiene, to prevent cross-contamination. Finally, regular
cultures of throat swabs and faeces are performed
(monitoring the effectiveness of SDD).
Studies on SDD
There are presently no studies that have compared the whole
regimen, as already described, with regimens using only
nonabsorbable antibiotics in the oral cavity and the rest of
the digestive tract, or with nonabsorbable antibiotics in the
oral cavity alone. We specifically chose to review the trials in
which the whole regimen of SDD (oropharyngeal, intestinal
and systemic) has been studied since we consider the first
three aspects of the original SDD regimen essential to
control the three types of infection in ICU patients (primary
endogenous infections, secondary endogenous infections
and exogenous infections).
Twelve prospective, randomized studies in which SDD is
compared with controls (Table 1) [14–25] and five meta-
analyses including only prospective studies have been
published in the past 15 years. A large prospective,
controlled, randomized trial has recently been finished. At
present, data from this trial are only available in abstract form
[11].
Table 1
Selective decontamination of the digestive tract (SDD) schemes and outcomes of prospective randomized trials
Pulmonary infection 
Number of  incidence (%),  Mortality (%), 
Reference patients control versus SDD P value control versus SDD P value
Aerdts et al. [14] 88 69.2 vs 5.9 0.0001 15.4 vs 11.8 Not significant
Blair et al. [15] 256 34.4 vs 9.7 0.002 21.4 vs 10.5 Not significant
de Jonge et al. [11] 934 –a –a 22.9 vs 14.8 0.002
Cockerill et al. [16] 150 18.6 vs 5.3 0.03 21.3 vs 14.7 Not significant
Jacobs et al. [17] 79 9.3 vs 0 < 0.05 53.5 vs 38.8 Not significant
Kerver et al. [18] 96 85.1 vs 12.2 < 0.01 32.0 vs 28.5 Not significant
Krueger et al. [19] 546 11.1 vs 2.3 0.007 28.6 vs 19.6 Not significantb
Palomar et al. [20] 83 50.0 vs 17.1 0.005 31.0 vs 24.4 Not significant
Rocha et al. [21] 101 46.3 vs 14.9 < 0.001 44.4 vs 21.3 < 0.05c
Sanchez-Garcia et al. [22] 271 29.3 vs11.5 0.05 47.1 vs 38.9 Not significant
Ulrich et al. [23] 100 55.8 vs 14.6 < 0.001 53.8 vs 31.3 < 0.02c
Verwaest et al. [24] 440 11.4 vs 6.6 < 0.05 16.8 vs 15.5 Not significant
Verwaest et al. [24] 440 11.4 vs 7.0 < 0.05 17.6 vs 15.5 Not significant
Winter et al. [25] 183 34.8 vs 3.3 < 0.01 43.5 vs 36.3 Not significant
a Not evaluated.
b Overall intensive care unit mortality was not statistically different, but the mortality was significantly reduced for patients with Acute Physiology
and Chronic Health Evaluation II scores of 20–29 on admission.
c Not significant on intention-to-treat analysis.109
Effects on pneumonia
In the studies in which the original SDD regimen was
compared with standard care, the use of SDD significantly
reduced the incidence of pneumonia [14–25]. The reduction
was independent of the choice of systemic antimicrobial
agent, as well as the choice of topical antimicrobial agents,
since the effect of SDD on the incidence of pneumonia was
found in all the reviewed studies (Table 1).
Remarkably, the incidence of VAP in the control groups
varied from 9.3% [17] to 85.1% [18]. One reason for this
large variation may be differences in patient populations.
Another reason may be the difference in the way in which
pneumonia is diagnosed. In some studies, the diagnosis of
VAP was made on clinical, radiological and microbiological
criteria alone. It can be argued that in these studies the
reduction in respiratory tract infections is in fact a reduction
in colonization and purulent tracheobronchitis, and not a
reduction in pneumonia. Other studies used bronchoscopic
techniques, with quantitative cultures that usually cause the
incidence of VAP to be one-half of that with the diagnosis
made based on clinical, radiological and microbiological
criteria. But, also in these studies, the SDD regime still
demonstrated a significant reduction in the incidence of
pneumonia compared with conventional treatment.
Effects on mortality
Only two of the published studies demonstrated a reduced
mortality in SDD-treated patients compared with control
subjects [21,23]. In these studies the reported reduction in
mortality was found after exclusion of a number of patients. In
an intention-to-treat analysis the differences in mortality did
not reach significance [4]. Although in all studies but one the
number of patients that died in the SDD-treated group was
lower compared with the number of patients that died in the
control group [14–18,20,22,24,25], a significant effect of
SDD on mortality could not be demonstrated. This was due
to the small number of patients in those studies (i.e. all these
studies were underpowered).
A significant reduction in ICU mortality has been
demonstrated in two recent meta-analyses [4,5]. In the
analysis by D’Amico et al., the mortality was 24% in SDD-
treated patients and was 30% in controls [4]. In addition, one
recently published study showed a reduced mortality in
patients on SDD in midrange stratum with Acute Physiology
and Chronic Health Evaluation II scores of 20–29 on
admission [19]. We recently finished a prospective,
randomized, controlled study in 934 patients (medical and
surgical), presently unpublished, and found a significant
reduction in ICU mortality and hospital mortality [11].
Major concerns exist because the majority of studies was
performed in a nonblinded fashion. However, the results of the
two double-blind studies are comparable with the results of
the nonblinded studies in respect to the reduction of the
incidence of VAP (Table 1). Although a double-blind study is
the optimal design to determine the efficacy of an intervention,
only two of the aforementioned studies were double-blind
trials [21,22]. Because surveillance cultures will immediately
show which patient is receiving SDD and which patient is not,
it is not possible to perform a study in a blinded fashion.
Surveillance cultures are an integral part of microbiology for
SDD patients. They are necessary to enable monitoring of
the efficacy of SDD and the detection of exogenous infection
problems in the ICU. Furthermore, even if it would be
possible, the consequence of a blinded study is to create an
environment in which both regimens are used at the same
time. Under these circumstances the desired effects of SDD
would be less because of cross-contamination. This situation
has been dealt with in the study of de Jonge et al. [11] by
randomly admitting patients to separate units, which were
randomized to be using SDD or conventional treatment. Also,
as recently shown [26], the inverse relationship between
methodological quality score (e.g. blinded versus nonblinded
studies) and the benefit of SDD exists for the incidence of
VAP, but not for mortality. A well-designed trial can thus be
used to demonstrate the effect of SDD on mortality, whether
blinded or not.
Effects of SDD on antimicrobial resistance
It has been argued that the use of SDD may lead to the
emergence of antimicrobial resistance. However, in none of
the published prospective, randomized trials was there a
clinically significant harmful effect of SDD in respect to
superinfections, nor was there colonization with
microorganisms that had acquired resistance to the
antibiotics used.
Only two studies adequately analyzed the effects of SDD on
antimicrobial resistance [11,19]. The study by Krueger et al.
[19] demonstrated no remarkable differences between SDD-
treated patients and placebo-treated patients with respect to
the isolation of resistant bacteria. Although increasing
numbers of patients in both groups became colonized by
coagulase-negative staphylococci, enterococci resistant to
ciprofloxacin and gentamicin, and oxacillin-resistant
coagulase-negative staphylococci, methicillin-resistant S.
aureus (MRSA) was rarely isolated. The study by de Jonge et
al. demonstrated a decline in colonization with P. aeruginosa
and enterobacteriaceae that were resistant against
tobramycin, ceftazidime, imipenem and ciprofloxacin [11],
which is in contrast with the expectation of the skepticists of
SDD. In their study, no colonization with MRSA was found in
any patient and the incidence of colonization with
vancomycin-resistant entercocci (VRE) was very low (<2%).
Colonization with VRE was not influenced by the
administration of SDD.
Different effects could clearly have been found in ICUs with a
high prevalence of MRSA and VRE. SDD does exert
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selective pressure on MRSA. Indeed, increased colonization
with MRSA in SDD-treated patients has been reported in
ICUs with endemic MRSA [24,27]. However, no publications
exist reporting an increase in hospital outbreaks of MRSA in
countries with a low incidence of MRSA carriage in the
population. On the contrary, Staphylococcal and
Enterococcus spp. infections were uncommon and the level
of methicillin resistance did not change in a study on the
long-term effects of SDD by Hammond and Potgieter [28].
Although no studies showed increased colonization or
infection with VRE, it cannot be excluded that SDD has a
detrimental effect on VRE in situations were VRE is endemic.
On the other hand, the reduced prescription of systemic
broad-spectrum antibiotics in SDD-treated patients may also
lead to decreased incidence of VRE [22].
Conclusion
Taken together, the results of the individual studies and the
meta-analysis indicate a strong protective effect of the
original SDD scheme against VAP in critically ill patients. The
recent, as yet unpublished, study on SDD from our institution
supports the conclusion from the meta-analysis that mortality
is also reduced in SDD-treated patients. In hospitals with a
low prevalence of VRE and MRSA there is no data that show
increased resistance to those organisms. On the contrary,
resistance against Gram-negative aerobic bacteria
decreased in SDD patients compared with patients receiving
standard treatment.
Based on the present data, we recommend using SDD,
combining systemic, topical, oropharyngeal and intestinal
antibiotics, in critically ill patients. As the concept of SDD has
been shown to improve survival, more research is needed to
determine the optimal SDD regimen in situations in which
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